On July 2 local time, WHO held a press conference on the progress of new coronary pneumonia research and development. In response to the US’s "bought-out" recent production capacity of Redisive, WHO chief scientist Sumia Swaminathan said that global solidarity This is very important, as is the case with ridxivir and other drugs, as well as the vaccines that may be developed, which is a test for all humans.
Gilead, the manufacturer of Ridecive, has authorized several other pharmaceutical companies to produce the drug, and supply will rise in the coming weeks. Sumia Swaminathan pointed out that there are still a number of trials involving redisive, and it is unclear the efficacy of this antiviral drug against new coronary pneumonia, and WHO will continue to evaluate it. (Headquarters reporter Zhu He)